Company / Operating Income
Esperion Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$60.3M
FY2025
5-year range
-$226.7M / $60.3M
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
#42 of 204
Health Care
What the data says
Esperion Therapeutics, Inc.'s operating income of $60M is higher than 79% of companies in the Health Care sector (FY2025). Operating Income has increased for 4 consecutive years, from -$227M in FY2021 to $60M in FY2025.
Based on SEC 10-K filings.
$60M in FY2025. Top quartile in the Health Care sector.
Improved from -$156M to $60M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 204This company $60.3M Sector average $107.7M
▼
-44.0% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s operating income has grown for 4 consecutive years.
- In FY2025, operating income increased 10.8% year-over-year.
- Ranks #42 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.3M | +10.8% |
| FY2024 | $54.4M | +135.0% |
| FY2023 | -$155.6M | +13.3% |
| FY2022 | -$179.5M | +20.8% |
| FY2021 | -$226.7M | -86.8% |
| FY2020 | -$121.4M | -30.4% |
| FY2019 | -$93.1M | +54.5% |
| FY2018 | -$204.6M | -21.1% |
| FY2017 | -$169.0M | -121.9% |
| FY2016 | -$76.2M | -52.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026